Search - tctmd.com

Displaying 21 - 40 of 516

Sort: Relevancy | Date

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Daily News

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

Yael L. Maxwell

January 23, 2025

News Daily News

EXCEL Data Highlight Bleeding Patterns After CABG, PCI for LM Disease

Yael L. Maxwell

December 05, 2024

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Caitlin E. Cox

October 31, 2024

Presentation TCT 2024

3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

Presenter: Hongbo Yang

October 30, 2024

Presentation TCT 2024

TCT 289: Different Efficacy of 12-Month Dual Antiplatelet Therapy Following Off-Pump Versus On-Pump Coronary Artery Bypass Grafting

Presenter: Woo Jin Jang

October 27, 2024

Presentation TCT 2024

TCT 401: Impact of >12-Month Versus =12-Month Dual Antiplatelet Therapy on Long-Term Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention

Presenter: Yao Jiang

October 27, 2024

Presentation TCT 2024

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Presenter: IFTIKHAR CH

October 27, 2024

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Todd Neale

September 01, 2024

News Conference News ESC 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

Michael O'Riordan

September 01, 2024

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

Advertisement

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

What’s Going to Be Hot at ACC 2025?

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

ACC/AHA Release New Comprehensive ACS Guidelines

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

EXCEL Data Highlight Bleeding Patterns After CABG, PCI for LM Disease

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

TCT 289: Different Efficacy of 12-Month Dual Antiplatelet Therapy Following Off-Pump Versus On-Pump Coronary Artery Bypass Grafting

TCT 401: Impact of >12-Month Versus =12-Month Dual Antiplatelet Therapy on Long-Term Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

DES Best for In-Stent Restenosis, but DCBs Also Viable

August 2024 Dispatch for the CV Team

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content